Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCrimson Tide Regulatory News (TIDE)

Share Price Information for Crimson Tide (TIDE)

Share Price is delayed by 15 minutes
Get Live Data
92.50    0.00 (0.00%)
Bid:
90.00
Ask:
95.00
Spread: 5.00 (5.556%)
Market Cap: £6.08m
TIDE Live PriceLast checked at - London Stock Exchange

Intraday Crimson Tide Share Chart

Trading Update

3 Feb 2022 07:00

RNS Number : 5042A
Crimson Tide PLC
03 February 2022
 

3 February 2022

Crimson Tide Plc

Period end Trading Update

 

Financial

 

Crimson Tide Plc (TIDE) ("Crimson Tide" or "The Company"), the provider of the mpro5 solution, is pleased to provide the following trading update ahead of publishing its full year results for the year to 31 December 2021.

 

Revenue for the year was slightly ahead of expectations of £4.0 million. Following the fund raise in April 2021, which saw a number of highly respected institutional investors join the shareholder register, the deployment of investment capital led to slightly smaller losses for the year than the £700k expected at the EBIT and PBT levels.

Results were boosted by increased mpro5 subscribers (for new and existing clients alike), with our activities in rail and food safety standing out in terms of additions to base subscriptions.

Year-end cash stood in excess of £5.5 million following good performance by mpro5 and slight delays in deploying capital, mainly through supplier delays.

Operations

Notable successes during the year included:

· the rollout of mpro5 in schools across the country with Chartwells

· successful pilots including Internet of Things (IoT) sensors in the rail and facilities management sectors

· International expansion, with an office in Raleigh, North Carolina now established and transactions in Scandinavia and Canada

· Significant hires in sales, marketing and development

· Master Services Agreement signed with Compass Group

 

We are implementing a strategy to bring all versions of mpro5 on to one consolidated platform. Scalability both domestically and internationally will benefit from this approach. A single platform strategy will bring the benefits of our different vertical solutions into one codebase.

We continue to pursue IoT growth and are working on a partnership with a global player, where mpro5 will become a feature of their partner ecosystem. Our current vertical focus areas in Transportation, Facilities Management and Retail as well as some exciting opportunities for mpro5 to help the NHS with 50-point checks continue to provide a growing pipeline.

Outlook

Our goal is to continue to standardise mpro5 for a wide range of businesses and we are deploying our capital in developing our platform in international, and vertical markets. This will enable us to scale, whether it is through partner acquisition, direct sales to microbusiness or our enterprise-level offering. Our goal remains to reach EBITDA breakeven during 2022, however, we believe that top-line growth is open to us across our sectors and internationally and we will invest capital further where we see opportunity. The Directors remain confident in future growth and believe that our ability to scale the business has never been greater.

Full-year results are expected to be published in early April. The numbers in this update remain subject to final close procedures and audit.

Enquiries:

 

Crimson Tide plc

Barrie Whipp / Luke Jeffrey

 

+44 1892 542444

 

finnCap Ltd (Nominated Adviser and Broker)

Julian Blunt / James Thompson - Corporate Finance

Andrew Burdis - Corporate Broking

 

+44 20 7220 0500

 

 

 

Alma PR (Financial PR)

Josh Royston

 

+44 7780 901979

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTTTMJTMTTMBBT
Date   Source Headline
4th Jan 20235:00 pmRNSHolding(s) in Company
1st Dec 20227:00 amRNSDirector dealing
17th Nov 20227:00 amRNSSignificant contract expansion and extension
27th Sep 20227:00 amRNSInterim Results
25th Aug 20227:00 amRNSDirector Dealing
3rd Aug 20227:00 amRNSChange of Auditor
2nd Aug 20227:00 amRNSBoard Changes
25th Jul 20227:00 amRNSContract Win
19th Jul 20227:00 amRNSMultiyear contract win with major wholesaler
30th Jun 202211:27 amRNSResults of AGM & Statement
16th Jun 20224:30 pmRNSAnnual Report and Notice of AGM
7th Apr 20227:00 amRNSPreliminary Results
10th Feb 20227:00 amRNSContract Win and Strategic Partnership
3rd Feb 20227:00 amRNSTrading Update
7th Dec 20217:00 amRNSMaster Service Agreement with Compass Group
12th Nov 20217:00 amRNSDirectorate Change
11th Oct 202110:59 amRNSPDMR Dealing
28th Sep 20217:00 amRNSInterim Results
29th Jun 20213:08 pmRNSResult of AGM
16th Jun 20217:00 amRNSNorth America Appointment
4th Jun 20217:00 amRNSAnnual Report and Notice of AGM
4th May 20212:22 pmRNSTotal Voting Rights
28th Apr 202110:34 amRNSHolding(s) in Company
27th Apr 20217:00 amRNSHolding(s) in Company
26th Apr 20217:00 amRNSHolding(s) in Company
23rd Apr 20214:25 pmRNSHolding(s) in Company
23rd Apr 202110:37 amRNSPDMR Dealings
23rd Apr 202110:36 amRNSHolding(s) in Company
22nd Apr 202111:45 amRNSResult of General Meeting and Total Voting Rights
20th Apr 20217:00 amRNSContract Win
1st Apr 20213:52 pmRNSResult of Placing
1st Apr 202112:01 pmRNSPlacing to raise up to £6.0 million
1st Apr 202112:00 pmRNSPreliminary Results
18th Mar 20217:00 amRNSContract Win
1st Feb 20219:28 amRNSHolding(s) in Company
28th Jan 20217:00 amRNSAppointment of Director
26th Jan 20217:00 amRNSPilot with World Federation of Haemophilia
18th Jan 20219:36 amRNSHolding(s) in Company
12th Jan 20214:07 pmRNSHolding(s) in Company
7th Jan 20212:30 pmRNSHolding(s) in Company
23rd Dec 202012:15 pmRNSClarification re Grant of Options
22nd Dec 202010:45 amRNSGrant of Options under the Company's EMI Scheme
4th Dec 202011:35 amRNSHolding(s) in Company
17th Nov 20207:00 amRNSContract Wins
12th Nov 20204:27 pmRNSDirector/PDMR Shareholding
6th Nov 20201:15 pmRNSPDMR dealing
26th Oct 202010:08 amRNSHolding(s) in Company
5th Oct 20209:16 amRNSHolding(s) in Company
18th Sep 20207:00 amRNSInterim Results
14th Sep 20202:06 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.